Funded projects include tissue engineering, fetal programming in metabolic syndrome, chromosomal abnormalities, translational imaging in cardiology, and nanobeam materials More
Ten University of Western Ontario researchers have been named among the recipients of more than $21-million in financial support from the province for health research. More
GenOdyssee S.A. announced today that the Journal of antimicrobial Agents and Chemotherapy (AAC*), has accepted a manuscript describing stronger and more sustained inhibitory effect of GenOdyssee's lead antiviral drug candidate, GEA007.1 More
STOCKHOLM, SWEDEN—Her Majesty the Queen of Sweden will officially open the Salk Institute's annual International Council meeting at the Grand Hotel in Stockholm. More
Data describing the higher antiviral potency of GenOdyssee's lead antiviral IFN alpha variant GEA007.1 compared to IFN alpha 2b, against HCV replication, will be presented in Paris, at the International Symposium on Viral Hepatitis and Liver Disease More
All rights reserved. Terms and Conditions | Contact us
